Repeatability of Metabolically Active Volume Measurements with18F-FDG and18F-FLT PET in Non–Small Cell Lung Cancer
Open Access
- 15 November 2010
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 51 (12) , 1870-1877
- https://doi.org/10.2967/jnumed.110.077255
Abstract
In addition to tumor size measurements with CT, there is a need for quantitative measurements of metabolic active volumes, possibly adding to tracer uptake measurements in oncologic response evaluation with PET. The aim of this study was to evaluate the metabolic volume test–retest variability in 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) PET studies for various commonly used volumes of interest (VOIs) and the dependence of that variability on lesion size and relative radiotracer uptake. Methods: Twenty non–small cell lung cancer patients were scanned twice with 18F-FDG (n = 11) or 18F-FLT (n = 9). VOIs were defined on images reconstructed with normalization- and attenuation-weighted ordered-subset expectation maximization using 4 isocontours (A41%, A50%, and A70% thresholds, adapted for local background, and 50% threshold, uncorrected for background). Statistical analysis comprised intraclass correlation coefficients and Bland–Altman analysis. Results: In the 18F-FDG and 18F-FLT groups, 34 and 20 lesions, respectively, were analyzed. Median volumes at the A50% threshold were 3.31 and 2.19 mL (interquartile range, 1.91–8.90 and 1.52–7.27 mL) for 18F-FDG and 18F-FLT, respectively. Intraclass correlation coefficients were greater than 0.9, with the exception of the A70%-based metabolic volumes for 18F-FLT. For lesions greater than 4.2 mL, repeatability coefficients (RCs = 1.96 × SD) of the percentage difference ranged from 22% to 37% for 18F-FDG and from 39% to 73% for 18F-FLT, depending on the VOI method being used. Repeatability was better for larger tumors, but there was no dependence on absolute uptake (standardized uptake value). Conclusion: Results indicate that changes of greater than 37% for 18F-FDG and greater than 73% for 18F-FLT (1.96 × SD) for lesions with A50% metabolic volumes greater than 4.2 mL represent a biologic effect. For smaller lesions (A50% VOI < 4.2 mL), an absolute change of 1.0 and 0.9 mL for 18F-FDG and 18F-FLT, respectively, is biologically relevant. Considering the balance between the success rate of automatic tumor delineation and repeatability of metabolic volume, a 50% threshold with correction for local background activity (A50%) seems optimal among the VOI methods evaluated.Keywords
This publication has 15 references indexed in Scilit:
- PET CT Thresholds for Radiotherapy Target Definition in Non–Small-Cell Lung Cancer: How Close Are We to the Pathologic Findings?International Journal of Radiation Oncology*Biology*Physics, 2010
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Standards for PET Image Acquisition and Quantitative Data AnalysisJournal of Nuclear Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trialsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Reproducibility of Intratumor Distribution of 18F-Fluoromisonidazole in Head and Neck CancerInternational Journal of Radiation Oncology*Biology*Physics, 2008
- Agreement Between Methods of Measurement with Multiple Observations Per IndividualJournal of Biopharmaceutical Statistics, 2007
- Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trialEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging The Visual Response Score and the Change in Total Lesion GlycolysisClinical Positron Imaging, 1999